[Berberine inhibits cardiac fibrosis of diabetic rats].
Objective To explore the effect of berberine on cardiac fibrosis of diabetic rats by observing the expressions of serum transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF) , collagen type 1 (Col1) and collagen type 3 (Col3) in myocardial tissues of diabetic rats after berberine treatment. Methods The diabetic model was induced by intraperitoneal injection of streptococci (STZ). Forty-three diabetic rats were randomly divided into diabetic model group (n=9), berberine treated groups of different doses [50, 100, 150 mg/(kg.d), gavage administration for 12 weeks; n=9, 9, 8 respectively], and metformin group as positive control (n=8); other 8 normal rats served as a negative control group. After the last administration, fasting blood glucose, left ventricular systolic pressure (LVSP) and left ventricular end diastolic pressure (LVEDP) were measured; rats' heart were taken to calculate the heart mass index (HMI); ELISA was used to detect the serum levels of TGF-β1 and CTGF; collagenous fibers in cardiac tissues were tested by Masson staining; collagen volume fraction (CVF) was measured by image analysis; Col1 and Col3 in cardiac tissues were determined by Western blotting. Results Compared with the normal control group, the fasting blood glucose, LVSP, LVEDP absolute value, HMI, the degree of cardiac fibrosis, the expressions of TGF-β1, CTGF, Col1 and Col3 significantly increased in the model group. All indexes mentioned above were reduced obviously in berberine treated groups of 100 and 150 mg/(kg.d). Conclusion Berberine improves cardiac fibrosis in diabetic rats through down-regulating the expressions of TGF-β1 and CTGF and reducing the synthesis and deposition of Col1 and Col3.
Department of Biochemistry and Molecular Biology, Shangqiu Medical College, Shangqiu 476100, China. *Corresponding author, E-mail: lukun198410208@163.com.
Kun
K
Lu
Department of Biochemistry and Molecular Biology, Shangqiu Medical College, Shangqiu 476100, China.
Yongjie
Y
Shen
Department of Preventive Medicine, Shangqiu Medical College, Shangqiu 476100, China.
Jinfeng
J
He
Department of Biochemistry and Molecular Biology, Shangqiu Medical College, Shangqiu 476100, China.
Guoling
G
Liu
Department of Biochemistry and Molecular Biology, Shangqiu Medical College, Shangqiu 476100, China.
Wei
W
Song
D000818:Animals; D001599:Berberine / Q000008:administration & dosage*; D024061:Collagen Type III / Q000235:genetics / Q000378:metabolism; D055513:Connective Tissue Growth Factor / Q000235:genetics / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental; D058065:Diabetic Cardiomyopathies / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D005355:Fibrosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D006801:Humans; D008297:Male; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D053773:Transforming Growth Factor beta1 / Q000235:genetics / Q000378:metabolism
D024061:Collagen Type III; D053773:Transforming Growth Factor beta1; D001599:Berberine; D055513:Connective Tissue Growth Factor